CHRISTOPHER JANKOWSKI: Open Payments
NPI 1265114516 · AMMON, ID. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$1,193 in 49 payments from 13 companies in 2025. Trend: 2023 $71 · 2024 $1,201 · 2025 $1,193
Food & beverage: $955Education: $238
| Company | Payments | Amount |
|---|---|---|
| Teva Pharmaceuticals USA, Inc. | 11 | $315 |
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | 7 | $264 |
| ABBVIE INC. | 10 | $193 |
| Vanda Pharmaceuticals Inc. | 6 | $170 |
| Otsuka America Pharmaceutical, Inc. | 3 | $57 |
| Indivior Inc. | 3 | $53 |
| Janssen Pharmaceuticals, Inc | 2 | $34 |
| Lundbeck LLC | 2 | $34 |
| Supernus Pharmaceuticals, Inc. | 1 | $17 |
| Axsome Therapeutics, Inc. | 1 | $16 |
Products named: CAPLYTA, VRAYLAR, FANAPT, REXULTI, AUSTEDO XR, SUBLOCADE, UZEDY, SPRAVATO.
Industry payments across ID — which companies pay providers there.
